STOCK TITAN

PainReform Ltd - PRFX STOCK NEWS

Welcome to our dedicated news page for PainReform (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PainReform.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PainReform's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PainReform's position in the market.

Rhea-AI Summary
PainReform Ltd. (Nasdaq: PRFX) announced its participation at The Microcap Conference on January 30 - February 1, 2024, where CEO Ilan Hadar will present on Track 2 and Track 5. The company will also hold one-on-one meetings with investors and provided contact information for meeting requests and conference registration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
conferences
-
Rhea-AI Summary
PainReform Ltd. (Nasdaq: PRFX) reported in vitro test results comparing its lead product, PRF-110, with the industry leader as a topical analgesia for postoperative pain relief. PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading, including a greater ability to spread evenly due to its viscosity (PRF-110 1,500 cP vs. industry leader 3,000 cP).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PainReform Ltd. (Nasdaq: PRFX) announces a definitive agreement for the immediate exercise of outstanding warrants to purchase up to 467,896 ordinary shares at a reduced exercise price of $2.85 per share, registered pursuant to an effective registration statement on Form F-1 (File No. 333-274220).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
none
Rhea-AI Summary
PainReform Ltd. (Nasdaq: PRFX) reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy. The company provided a business update for the third quarter ended September 30, 2023, highlighting the progress of their lead drug candidate, PRF-110, targeting the post-operative extended pain relief market. The update includes details about the initiation of the second part of the Phase 3 trial in bunionectomy, with the enrollment of the first patients and plans for continued enrollment of up to 400 patients in the double-blind study at multiple clinical sites in the U.S. The update also covers the financial results for the nine months ended September 30, 2023, including research and development expenses, general and administrative expenses, financial income, net, and net loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
none
-
Rhea-AI Summary
PainReform plans to commence second part of Phase 3 trial for PRF-110 in Q4 2023, with results expected in mid-2024. Positive safety data from first part of trial suggests potential advantage over opioids. PRF-110 has key surgical benefits and addresses unmet need in postoperative pain market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
clinical trial
-
Rhea-AI Summary
PainReform announces positive safety and PK data of PRF-110 from Phase 3 clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
none
Rhea-AI Summary
PainReform CEO to attend H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.56%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.02%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.87%
Tags
offering
PainReform Ltd

Nasdaq:PRFX

PRFX Rankings

PRFX Stock Data

3.85M
1.09M
5.26%
25.53%
0.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Tel Aviv

About PRFX

painreform is a specialty pharmaceutical company that develops products for the treatment of pain. focused on reformulations of established pain drugs for the us fda 505(b)(2) regulatory pathway, painreform applies unique technologies to enhance efficacy, reduce adverse effects and increase convenience. our mission is to offer pain therapeutics with clinically meaningful benefits to both physicians and patients.